Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease.

@article{Guney2009AntifibroticEO,
  title={Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease.},
  author={Ibrahim Ethem Guney and Nedim Yılmaz Selçuk and L{\"u}tfullah Altintepe and Huseyin Atalay and Mustafa Kemal Başarali and Sadik B{\"u}y{\"u}kbaş},
  journal={Renal failure},
  year={2009},
  volume={31 9},
  pages={
          779-84
        }
}
AIMS Proteinuria and transforming growth factor beta (TGF-beta) are parameters that can lead to glomerulosclerosis and tubulointerstitial fibrosis. All components of the renin-angiotensin-aldosterone system (RAAS) activate the TGF-beta. Aldosterone may not be inhibited with angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin receptor blockers (ARBs) due to aldosterone escape. We aimed to evaluate the effect of spironolactone on parameters leading to fibrosis. METHODS This… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 14 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 28 REFERENCES

Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.

  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2006
VIEW 1 EXCERPT